Chronic graft-versus-host disease (cGVHD) represents one of the most significant long-term complications affecting survivors of allogeneic haematopoietic cell transplantation (HCT), according to a comprehensive review published in Nature Reviews Disease Primers (June 2026). The condition, which emerges weeks to months after transplantation when donor immune cells attack host tissues, affects multiple organ systems and profoundly impacts quality of life in cancer patients who have undergone bone marrow or stem cell transplants. This Primer, authored by Ye and colleagues, consolidates current evidence on epidemiology, pathophysiology, diagnostic criteria, and management strategies — offering clinicians and researchers a practical synthesis of what is known and what remains unclear about this complex complication.
Key takeaways
- Chronic graft-versus-host disease is a major late complication of allogeneic haematopoietic cell transplantation, affecting quality of life across multiple organ systems
- Diagnosis requires integration of clinical features with histopathological and laboratory findings, not any single test
- Management strategies span immunosuppression, targeted therapies, and supportive care tailored to organ involvement
- Patient quality-of-life outcomes and long-term survival remain critical but understudied aspects of cGVHD care
Study at a Glance
| Source | Nature Reviews Disease Primers |
| Article type | Comprehensive Review Primer |
| Topic | Chronic graft-versus-host disease: epidemiology, mechanisms, diagnosis, management |
| Author(s) | Ye et al. |
| Publication date | 11 June 2026 |
Organ systems affected by chronic graft-versus-host disease
Relative frequency of organ involvement in cGVHD cases, based on published cohort data
Source: Nature Reviews Disease Primers, 2026 | Georgian Medical Journal News
Understanding the epidemiology and pathophysiology of cGVHD
Chronic graft-versus-host disease emerges as a consequence of the complex immunological interplay that follows allogeneic HCT. According to the Nature Reviews Disease Primers analysis by Ye and colleagues, the condition differs mechanistically from acute GVHD (which appears within 100 days post-transplant) and involves both donor T-cell responses against host tissues and dysregulation of regulatory immune mechanisms. The pathophysiology integrates multiple pathways: alloreactivity of donor T cells, disruption of the epithelial barrier, loss of regulatory T-cell function, and chronic inflammation mediated by B cells and other innate immune cells.
The epidemiology of cGVHD varies depending on the transplant population studied — including factors such as donor source (matched sibling versus unrelated donor), conditioning intensity, and immunosuppressive regimens used. Patients who experience acute GVHD carry an elevated risk of developing cGVHD subsequently, though de novo cGVHD (occurring without prior acute GVHD) also occurs. This heterogeneity reflects the complex host and donor factors that drive the condition, underscoring why a one-size-fits-all approach to diagnosis and management is insufficient.
Diagnostic challenges in a multi-system disease
One of the central themes in the Ye et al. Primer is that cGVHD diagnosis cannot rely on a single laboratory test or imaging modality. Instead, clinicians must integrate clinical history, physical examination findings, histopathological evidence, and specialized investigations (such as pulmonary function testing for lung involvement or ophthalmological assessment for ocular manifestations). The 2014 National Institutes of Health (NIH) consensus criteria, which emphasize diagnostic and distinctive features for different organs, remain central to contemporary practice.
Diagnostic complexity is heightened by mimicry — other conditions, such as autoimmune disorders or medication-induced skin reactions, can resemble cGVHD. Histopathology, while informative, is not uniformly sensitive across all affected organs. For instance, oral cGVHD may present as lichen planus–like changes or xerostomia, while pulmonary cGVHD (bronchiolitis obliterans syndrome) requires pulmonary function testing and high-resolution computed tomography (HRCT) alongside clinical assessment. Clinical Updates on transplant complications increasingly emphasize the importance of multidisciplinary assessment teams to ensure accurate and timely diagnosis.
Chronic graft-versus-host disease diagnosis integrates clinical features, histopathology, and organ-specific investigations across skin, mouth, eyes, lungs, liver, and other tissues — requiring coordinated specialist input and adherence to NIH consensus criteria.
— Ye et al., Nature Reviews Disease Primers (June 2026)
Management strategies: from immunosuppression to supportive care
The therapeutic landscape for cGVHD has evolved significantly in recent years, with approaches spanning immunosuppressive drugs, targeted biologics, and supportive interventions. According to the Ye and colleagues review, initial management typically involves corticosteroids combined with calcineurin inhibitors (tacrolimus or cyclosporine) or other immunosuppressive agents. However, the optimal choice of initial therapy and the sequencing of agents for steroid-refractory cGVHD remain areas of active investigation and clinical debate.
Targeted therapies now represent an expanding armamentarium. JAK inhibitors (such as ruxolitinib), which were approved by the United States Food and Drug Administration (FDA) for steroid-refractory cGVHD, exemplify how mechanistic understanding of cGVHD pathophysiology — particularly dysregulated JAK-STAT signalling in immune cells — can translate into clinical interventions. Other emerging approaches include photopheresis, mesenchymal stem cell therapy, and newer immunosuppressive agents, each with varying levels of evidence and clinical application. Pharmacy and prescribing guidance increasingly addresses sequencing decisions and drug interactions in transplant survivors on complex immunosuppressive regimens.
Supportive care is equally vital. Management of cGVHD encompasses organ-specific interventions: topical corticosteroids and calcineurin inhibitors for skin disease, artificial saliva and oral care for mucositis, cyclosporine eye drops or systemic interventions for ocular involvement, and nutritional support for gastrointestinal cGVHD. The integration of rehabilitation services, psychological support, and dietary counselling reflects recognition that cGVHD is not solely a medical problem but a condition with profound functional and psychosocial consequences.
Quality of life and future research directions
A critical theme emerging from the Nature Reviews Primer by Ye and colleagues is the substantial gap between our understanding of cGVHD pathophysiology and our knowledge of how the disease affects patients’ daily functioning and well-being. Chronic GVHD survivors often experience fatigue, reduced physical capacity, social withdrawal, and diminished quality of life — effects that may persist even when the disease is medically controlled or in remission. Yet systematic assessment of these dimensions remains inconsistent across transplant centres, and interventions specifically designed to improve functional outcomes remain limited.
Future research priorities identified in the Primer include: (1) better prognostic models that integrate biomarkers with clinical features to predict trajectory and treatment response; (2) head-to-head trials comparing emerging therapies to establish evidence-based treatment algorithms; (3) longitudinal studies of quality of life, functional capacity, and late effects in cGVHD survivors; and (4) investigation of prevention strategies to reduce cGVHD incidence. The complexity of these questions underscores the need for collaborative, multi-centre research networks and investment in long-term follow-up studies — domains where global health initiatives and transplant registries can play a crucial coordinating role.
What this means
Frequently asked questions
How soon after transplantation does chronic GVHD typically appear?
Chronic GVHD usually emerges weeks to months after allogeneic haematopoietic cell transplantation, in contrast to acute GVHD which develops within the first 100 days. According to the Ye et al. review, onset can be as early as 100–150 days post-transplant, but median time to diagnosis often extends beyond 6 months, particularly for de novo cGVHD with no prior acute GVHD history.
Is chronic GVHD always preventable?
No single prevention strategy is 100% effective. The Primer notes that standard prophylaxis (typically involving methotrexate and calcineurin inhibitors) reduces incidence, but cGVHD remains common — particularly in recipients of unrelated-donor transplants or those receiving myeloablative conditioning. Research into improved prophylactic regimens and biomarker-guided prevention approaches is ongoing.
Can chronic GVHD be cured, or is it a lifelong condition requiring continuous management?
Some patients achieve complete resolution of cGVHD with successful treatment, while others require ongoing immunosuppression for extended periods. According to the Ye and colleagues analysis, the trajectory varies widely: some patients plateau on low-dose corticosteroids, others achieve discontinuation of all immunosuppression, and some experience chronic active disease. Individualised long-term follow-up and symptom-guided de-escalation of therapy are now standard practice.
The publication of this comprehensive Primer in Nature Reviews Disease Primers reflects both the clinical significance of chronic GVHD and the field’s commitment to synthesising evolving evidence for clinicians and researchers. As transplant survival improves and the number of long-term survivors grows, cGVHD management — spanning rigorous diagnosis, optimised immunosuppression, targeted therapies, and quality-of-life-centred supportive care — will remain a defining challenge in haematology and transplant oncology. Addressing the identified research gaps, particularly regarding long-term functional outcomes and prevention strategies, will be essential to improving the lived experience of haematopoietic cell transplant survivors worldwide.
Source: Chronic graft-versus-host disease, Nature Reviews Disease Primers
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
